News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Taiho Pharmaceutical Licensed To Develop And Sell ABRAXANE Anti-Cancer Agent By American BioScience, Inc.
November 21, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Tokyo (JCN) Nov 21, 2005- Taiho Pharmaceutical announced on November 16 that it has signed a licensing agreement with American BioScience for ABRAXANE, an anti-cancer agent. Under the agreement terms, Taiho will develop and sell the agent in Japan.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Asia
MORE ON THIS TOPIC
Deals
Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen
October 2, 2026
·
2 min read
·
Tristan Manalac
Layoffs
Foghorn lays off 40% of staff after Lilly collaboration ends
October 1, 2026
·
2 min read
·
Angela Gabriel
Manufacturing
Fresenius Kabi manufacturing plant hit with FDA warning letter after adverse events
October 1, 2026
·
2 min read
·
Nick Paul Taylor
Immunology and inflammation
Sanofi pays Regeneron $1B upfront to continue search for Dupixent successor
October 1, 2026
·
3 min read
·
Tristan Manalac